As of Friday close, Fate Therapeutics Inc.’s (NASDAQ:FATE) stock was up $2.41, moving up 11.05 percent to $24.22. The average number of shares traded per day over the past five days has been 2,545,920 shares. 2 times new highs have been achieved over the past 5 days, with a $0.06 gain in that time frame. In the last twenty days, the average volume was 1,624,020, while in the previous 50 days, it was 1,386,234.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, FATE stock retreated -37.79%. Shares of the company fell to $20.49 on 05/12/22, the lowest level in the past month. A 52-week high of $97.43 was reached on 01/03/22 after having rallying from a 52-week low of $20.49. Since the beginning of this year, FATE’s stock price has dropped by -58.61% or -$34.29, and marked a new high 1 time. However, the stock has declined by -75.14% since its 52-week high.
Fate Therapeutics Inc. (FATE) last reported insider trading activity 22 days ago on Apr 22. Wolchko J Scott, the President and CEO of the company, disposed of 10,000 shares for $34.59 on Apr 22. It resulted in a $345,911 divestment by the insider. Wolchko J Scott sold 30,000 shares at an average price of $35.00 on Apr 21. The insider now owns 431,546 shares following the transaction. On Apr 19, Chief Medical Officer Chu Yu-Waye sold 4,062 shares at $35.37 apiece. The transaction was valued at $143,673.
The stock’s beta is 1.69. Besides these, the trailing price-to-sales (P/S) ratio of 41.74, the price-to-book (PB) ratio of 3.69.
In the three months ended March 30, Fate Therapeutics Inc.’s quick ratio stood at 7.70, while its current ratio was 7.70, showing that the company is able to pay off its debt. Based on annual data, FATE earned $272.84 million in gross profit and brought in $55.85 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -32.00%. Return on equity (ROE) for the past 12 months was -33.30%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. FATE’s revenue rose 39.49% to $17.07 million during the quarter, while net income inched up to $18.41 million. While analysts expected Fate Therapeutics Inc. to report -$0.76 quarterly earnings, the actual figure was -$0.68 per share, beating the consensus estimate by 10.50%. During the quarter, the company generated -$69.74 million in EBITDA. The liabilities of Fate Therapeutics Inc. were 224.99 million at the end of its most recent quarter ended March 30, and its total debt was $114.82 million. The value of shareholders’ equity is $96.63 million.
This quick technical analysis looks at Fate Therapeutics Inc.’s (FATE) price momentum. With a historical volatility rate of 128.92%, the RSI 9-day stood at 37.68% on 13 May.
With respect to its five-day moving average, the current Fate Therapeutics Inc. price is up by +0.25% percent or $0.06. At present, FATE shares trade -35.88% below its 20-day simple moving average and -59.71% percent below its 100-day simple moving average. However, the stock is currently trading approximately -26.72% below its SMA50 and -71.85% below its SMA200.
Stochastic coefficient K was 11.51% and Stochastic coefficient D was 8.35%, while ATR was 3.05. Given the Stochastic reading of 24.35% for the 14-day period, the RSI (14) reading has been calculated as 36.85%. As of today, the MACD Oscillator reading stands at -2.44, while the 14-day reading stands at -4.56.
Fate Therapeutics Inc. (FATE) has been rated Buy by analysts. According to 0 brokerage firms , FATE is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Fate Therapeutics Inc. stock as buy, with 16 recommending it as overweight.
With a median target price of $90.00, the current consensus forecast for the stock is $42.00 – $135.00. Based on these forecasts, analysts predict Fate Therapeutics Inc. (FATE) will achieve an average price target of $86.26.